In summary, recent preclinical mechanistic studies have indicated that the utilization of CSF-1R inhibition, such as through BLZ-945, as a standalone treatment for gliomas, may not be adequate to achieve a significant improvement in survival. The gene discussed is CSF1R; the disease is glioma.